KBC Pharmaceutical Company
KBC Pharmaceutical Company is a Tehran-based public company listed on the Iran Fara Bourse under Kimia. It imports, procures and distributes specialised medicines, vaccines, blood derivatives, oncology therapies and medical equipment across Iran. The company matters as a regulated channel for foreign healthcare suppliers and an investable participant in Iran’s import-dependent pharmaceutical supply chain.
Operations & footprint
Products and services
KBC Company is focused on pharmaceutical import, distribution, procurement, sale, and supply of specialized medicines and healthcare products, with particular relevance to vaccines, oncology-related products, blood derivatives, and imported medical or pharmaceutical goods. Its role is linked to regulated imports, healthcare procurement, supply continuity, and money-transfer constraints.
Operations and assets
The company operates a regulated import, procurement and distribution model centred on specialised pharmaceutical products and medical equipment. Its portfolio includes paediatric vaccines, blood derivatives and oncology drugs, supported by foreign-brand representation arrangements.
Geographic footprint
Headquartered in Tehran and serving the Iranian healthcare market.
Ownership & group structure
Reported scale
Scale note: For the financial year ending in 2026, operating income was approximately IRR 1,750 billion (Tomans stated in the underlying disclosure). Gross profit and net profit increased 434% and 476% year on year, respectively; foreign-currency import volume increased 310%.
Commercial and investment relevance
In the Hormuz investment graph, KBC connects healthcare demand, pharmaceutical imports, specialized medicine supply, distributor networks, regulatory approvals, and money-transfer friction. It is useful for screening import-dependent healthcare segments, supply-shortage risk, distributor quality, counterparty exposure, and market-entry constraints for foreign pharmaceutical or medical-product companies. Commercial use should verify current licenses, product portfolio, principals or suppliers, payment channels, sanctions exposure, regulatory approvals, and real distribution capacity before reliance. For pharmaceutical manufacturers and medical-equipment suppliers, KBC is a route-to-market counterparty for regulated imports, product representation and distribution in Iran. Its role is particularly relevant in specialised therapies and vaccine procurement.
Constraints, risk & compliance
Key risks and constraints
Performance depends on maintaining product registrations, import quotas, vaccine-supply licences, foreign-principal relationships and access to foreign currency for imports. The product mix also exposes the business to procurement timing and concentration in specialised healthcare demand.
Sanctions and compliance considerations
Cross-border pharmaceutical procurement, banking and payment arrangements involving Iran require transaction-specific sanctions and export-control screening.
Need more than a public profile?
Ask Hormuz to investigate, verify or act locally around KBC Pharmaceutical Company. Tell us exactly what you need.
Connected Intelligence
Relevant geography, industry, market and execution context for this profile.
Frequently asked questions
Direct answers to the questions most likely to arise when reviewing this profile.
What does KBC Pharmaceutical Company do?
KBC imports, procures, distributes and supplies specialised medicines, vaccines, blood derivatives, oncology therapies and medical equipment in Iran.
Is KBC Pharmaceutical Company publicly listed?
Yes. KBC is listed on the Iran Fara Bourse under the ticker کيميا (Kimia).
Where is KBC Pharmaceutical Company based?
KBC is headquartered in Tehran, Iran.
Why is KBC relevant to international pharmaceutical suppliers?
KBC provides a regulated import and distribution route into Iran for specialised pharmaceutical and medical-equipment products, including vaccines and oncology treatments.